Skip to content
6-K

Foreign Interim / Material

Chemomab Therapeutics Ltd. CMMB

0001178913-25-002894

← back to feed
Filed
Aug 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q2 2025 · Jun 30, 2025 459.83M sh
Shares Diluted Q2 2025 · Jun 30, 2024 285.11M sh
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$6.14M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$7.19M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $5.45M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $6.07M
Stockholders Equity Q2 2025 · Jun 30, 2025 $9.7M
Stockholders Equity Q2 2025 · Mar 31, 2025 $10.39M
Stockholders Equity Q2 2025 · Dec 31, 2024 $13.54M
Stockholders Equity Q2 2025 · Jun 30, 2024 $9.99M
Stockholders Equity Q2 2025 · Mar 31, 2024 $13.33M
Stockholders Equity Q2 2025 · Dec 31, 2023 $17M
Current Liabilities Q2 2025 · Jun 30, 2025 $1.43M
Current Liabilities Q2 2025 · Dec 31, 2024 $3.22M
Total Liabilities Q2 2025 · Jun 30, 2025 $1.43M
Total Liabilities Q2 2025 · Dec 31, 2024 $3.43M
Current Assets Q2 2025 · Jun 30, 2025 $10.61M
Current Assets Q2 2025 · Dec 31, 2024 $16.04M
Total Assets Q2 2025 · Jun 30, 2025 $11.13M
Total Assets Q2 2025 · Dec 31, 2024 $16.96M
Eps Diluted Q2 2025 · Jun 30, 2025 $0.01
Eps Diluted Q2 2025 · Jun 30, 2024 $0.03
Eps Basic Q2 2025 · Jun 30, 2025 $0.01
Eps Basic Q2 2025 · Jun 30, 2024 $0.03
Sga Expense Q2 2025 · Jun 30, 2025 $1.97M
Sga Expense Q2 2025 · Jun 30, 2024 $1.74M
Rd Expense Q2 2025 · Jun 30, 2025 $3.78M
Rd Expense Q2 2025 · Jun 30, 2024 $6.08M
Net Income Q2 2025 · Jun 30, 2025 −$2.06M
Net Income Q2 2025 · Jun 30, 2025 −$5.38M
Net Income Q2 2025 · Mar 31, 2025 −$3.32M
Net Income Q2 2025 · Jun 30, 2024 −$3.63M
Net Income Q2 2025 · Jun 30, 2024 −$7.5M
Net Income Q2 2025 · Mar 31, 2024 −$3.87M
Operating Income Q2 2025 · Jun 30, 2025 $108M